RESEARCH TRIANGLE PARK, NC – July 10, 2012 – Quintiles today introduced Allume™, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume™ simplifies and organizes the complex and resource-intensive launch planning process; provides unique data-driven insights from 15 years of market entry experience across the globe; and taps Quintiles’ local market and therapeutic category expertise.
“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, Vice President, Consulting, Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets. Through Allume™ Quintiles provides the strategic thinking, local market knowledge, deep therapeutic insight and market access approaches to help our customers map and navigate a pathway to commercial success.”
A unique combination of Consulting, Clinical and Commercial expertise, paired with state-of-the-art software, Allume™ incorporates Quintiles’ years of biopharma product launch experience into flexible, seamless support that complements in-house capabilities. It can be fully customized to each company and product to help identify key market challenges, fast-track launch rollout and improve efficiency in resource management. This cost-effective solution allows companies to benefit from Quintiles’ product lifecycle expertise rather than assume the financial risk of creating their own infrastructure to support launch planning early in the commercialization process.
“Allume™ coordinates decision making around the late phases of development as well as the launch of an asset,” said Dr. Michael Ackermann, Senior Vice President, Global Commercial Solutions at Quintiles. “It is a well-structured and interactive way of accessing the expertise customers need without surrendering strategic control of their asset.”
About Allume™ from Quintiles
Allume™ combines Quintiles’ experience and expertise, secondary research and customized primary research to generate an assessment of the opportunity (including forecast) and insights into what is uniquely required to successfully commercialize your product. Blending these outputs with our regulatory, clinical, marketing, market access and sales operations expertise creates a strategic plan and tactical implementation roadmap. A sophisticated yet intuitive web-based platform plus dedicated project management ensures that the plan is executed in an efficient and timely way.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.